Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma

Table 1

Frequency of TP53 point mutations reported in rhabdomyosarcoma.

Study size	Authors	Exons sequenced	Number of mutations	Location of mutations
				Exon 5–8	Other
	Stratton et al., [20]	5–8	0/4	—
	Felix et al., [15]	4–8	1/6	Exon 6: R213P
	Toguchida et al., [23]	2–11	0/4	—
≤10	Latres et al., [17]	2–9	0/2		Exon 11: D393N
	Castresana et al., [13]	5–8	1/1	Exon 6: V218Y Y220C
	Würl et al., [24]	4–9	2/6	Exon 7: G245S
	Kusafuka et al., [16]	5–8	1/10	Exon 8: R273H
	Nawa et al., [19]	5–8	0/2	—
	Das et al., [14]	2–11	1/4
>10	Mulligan et al., [18]	5–8	2/31	Exon 5: G137V; Exon 8: R282W
	Taylor et al., [22]	5−9	1/20	Exon 5: del nt; 1004–1017
	Takahashi et al., [21]	5−9	9/45	Exon 6: E204G, R209T, P223R; Exon 7: M243T, G245C, N247D, R249G; Exon 8: C291G, P295H
Total TP53 mutations		18/135 (13.3%)